Vistagen Therapeutics, Inc. (VTGN) News
Track canonical SquawkNews coverage tagged to VTGN, Vistagen Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 15 indexed stories across 6 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
VTGN directors elected, say on pay approved, auditor reappointed
The annual meeting passed all proposals, including election of four directors, approval of executive compensation and reappointment of KPMG as auditor for FY 2027.
EQUITY | Sep 10, 2026, 04:54 PM UTC
H
VTGN - Vistagen to Present at Psych Congress 2026
VTGN - Vistagen to Present at Psych Congress 2026
GEOPOLITICS | Sep 10, 2026, 12:32 PM UTC
L
Vistagen (VTGN) reports FY2027 first-quarter financial results
Vistagen (VTGN) reports its fiscal year 2027 first-quarter financial results alongside a corporate update, with no additional figures included in the provided material.
EARNINGS | Aug 14, 2026, 12:32 PM UTC
L
VTGN - Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Click For Rel
VTGN - Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder
EQUITY | Aug 06, 2026, 12:30 PM UTC
H
Premarket Gainers: RAIN +101.87%
Top premarket gainers
EQUITY | Aug 04, 2026, 09:40 AM UTC
H
SRX Global Acquires Stake in Vistagen
SRX Global buys stake in Vistagen Therapeutics
MNA | Aug 04, 2026, 09:00 AM UTC
L
VTGN Appoints Douglas Williamson to Board
VTGN appoints new board member
EQUITY | Jul 31, 2026, 12:30 PM UTC
L
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Inc. (NASDAQ: VTGN ) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study popula
REGULATION | Jun 30, 2026, 05:35 PM UTC
L
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Creative Medical Tech (NASDAQ: CELZ ) stock moved upwards by 242.5% to $2.77 during Tuesday's regular session. The market value of their outstanding shares is at $2.9 million. Cuprina Holdings (Cayman) (NASDAQ: C
EQUITY | Jun 30, 2026, 05:05 PM UTC
L
Nasdaq Gains Over 300 Points; Chicago PMI Falls In June
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 300 points on Tuesday. The Dow traded up 0.28% to 52,327.93 while the NASDAQ rose 1.31% to 26,157.23. The S&P 500 also rose, gainin
MACRO | Jun 30, 2026, 04:08 PM UTC
L
US Stocks Mixed; Home Prices Increase 1.1% In April
U.S. stocks traded mixed this morning, with the Dow Jones index falling around 0.2% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.18% to 52,091.03 while the NASDAQ rose 0.36% to 25,912.25. The S
RATES | Jun 30, 2026, 01:47 PM UTC
L
Vistagen Therapeutics shares are trading lower after the company announced topline results from the PALISADE-4 Phase 3 trial. Fasedienol did
Vistagen Therapeutics shares are trading lower after the company announced topline results from the PALISADE-4 Phase 3 trial. Fasedienol did not achieve its primary endpoint and there was no treatment difference between
EQUITY | Jun 30, 2026, 01:28 PM UTC
L
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
Trading Halt: Halt status updated at 8:15:00 AM ET: Quotation Resumption: News and Resumption Times
EQUITY | Jun 30, 2026, 12:15 PM UTC
H
Vistagen Announces Topline Results From Its PALISADE-4 Phase 3 Trial Of Intranasal Fasedienol To Treat Social Anxiety Disorder; Fasedienol D
PALISADE-4 was a U.S. multi-center, randomized, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy, safety, and tolerability of a single dose of fasedienol in reducing anxiety sympt
EARNINGS | Jun 30, 2026, 12:09 PM UTC
L
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending
EQUITY | Jun 30, 2026, 11:55 AM UTC